The revenue beat and narrowed expense guidance signal operational leverage. The $400M buyback (about 4% of market cap) adds a capital return element. Watch for KB803 IOLITE top-line results in February 2027 and KB111 interim data before year-end.
Drug in focus
KRYS drug pipeline →KB113
● Neutral Named in this 8-K- Impact
- Phase
- Pilot study (proof-of-concept, equivalent to early Phase 1/2)
- Time to market
- KB113 is in early-stage development with no registered Phase 2/3 trial and no defined regulatory timeline. The company is in discussions with the FDA to determine the clinical development plan. If a pivotal program is agreed upon and initiated in 2027, potential approval would likely be several years away, barring a breakthrough or accelerated pathway.
- Next catalyst
- None dated
What to watchWatch for Krystal Biotech's announcement of FDA alignment on KB113's clinical development plan, which will define whether the program advances into a registrational trial or requires additional dose-finding studies. The small pilot (n=3) provides proof-of-concept but the regulatory path and timeline remain undefined, making KB113 a pipeline story rather than a near-term catalyst.
Price Chart
Executive Summary
Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30% YoY, above the $126.5M consensus. GAAP diluted EPS was $2.05, above the $1.92 consensus. The company also announced a $400M share repurchase program and narrowed FY 2026 non-GAAP R&D and SG&A expense guidance to $155M-$165M from $175M-$195M. Positive early clinical data for KB113 in Gorlin syndrome was highlighted.
Key Financial Metrics
Key Facts
- Q3 2026 VYJUVEK global net product revenue of $127.3M, up 30% YoY from $97.8M
- GAAP diluted EPS of $2.05 vs consensus of $1.92
- Board authorized share repurchase program of up to $400 million
- FY 2026 non-GAAP R&D and SG&A expense guidance narrowed to $155M-$165M from $175M-$195M
- KB113 pilot study showed >80% of assessed BCC lesions with clinical regression in Gorlin syndrome patients
- Cash and investments totaled $1.2 billion as of September 30, 2026
- Pricing negotiations completed in Germany and Italy; Italy launch expected in early 2027
Financial Impact
Q3 revenue of $127.3M beat consensus by approximately 0.6%; EPS of $2.05 beat consensus by approximately 6.8%
Risk Factors
- Net income declined YoY from $79.4M to $63.1M due to a $48.5M swing in income tax expense
- KB801 enrollment slower than expected due to narrow eligibility criteria and placebo-controlled design
- Pricing negotiations in France not expected until at least 2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001711279-26-000072 |
| Document: krys-20261102.htm | 0001711279-26-000072 |
| Document: 0001711279-26-000072-index-headers.html | 0001711279-26-000072 |
| Document: 0001711279-26-000072-index.html | 0001711279-26-000072 |
| Document: 0001711279-26-000072.txt | 0001711279-26-000072 |
| 8-K Data (Synthetic) | 0001711279-26-000072 |
Track record
18 reports on KRYS
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +26.60% at T+60 after the May 4, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 Viewing No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $295.90 Now $297.90 +0.68% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Bearish 5/10 Entry $332.29 Now $297.90 +10.35% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
- Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
- Oct 15, 20264w ago 8-K Bullish 6/10 Entry $330.00 to $305.68 Now $297.90 −9.73% ▼ −7.37% −5.47% vs SPY
- Sep 4, 202610w ago Insider Cluster Bearish 5/10 Entry $351.26 to $326.81 Now $297.90 +15.19% ▲ +6.96% +8.67% vs SPY
- Aug 14, 202613w ago 144 Neutral 2/10 Entry $335.73 to $336.68 Now $297.90 −11.27% ▲ +0.28% +2.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers